RecruitingNot ApplicableNCT06066606

U-LABA/ICS Effects on Exercise Performance, Vilanterol

Physiological Response to U-LABA/ICS With Emphasis on Exercise Performance, Vilanterol


Sponsor

Morten Hostrup, PhD

Enrollment

30 participants

Start Date

Oct 3, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate


Eligibility

Min Age: 18 YearsMax Age: 39 Years

Inclusion Criteria3

  • Age 18-39
  • Physically active > 5 h weekly
  • Maximal oxygen consumption classified as high or very high

Exclusion Criteria10

  • Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid
  • ECG abnormality
  • ACQ score > 1.5
  • Severe bronchial hyperreactivity as determined by mannitol test
  • FEV1/FVC ratio < 0.7 determined with spirometry
  • Chronic illness determined to be a potential risk for participant during study
  • In chronic treatment with medication that may interfere with study results
  • Pregnancy
  • Smoker
  • Blood donation during the past 3 months

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVilanterol and Fluticasone Furoate (low dose)

Participants are administered 25 µg of vilanterol + fluticasone furoate

DRUGVilanterol and Fluticasone Furoate (high dose)

Participants are administered 100 µg of vilanterol + fluticasone furoate

DRUGPlacebo

Participants are administered placebo


Locations(1)

August Krogh Building

Copenhagen, DK, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06066606


Related Trials